5[1]Morishima I,Sone T,Oknmura K,at al.Angiographie noreflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction[J].J Am Coll Cardiol,2000,36(4):1202-1209. 被引量：1
6[2]Kawano H,Hayashida T,Ohtani H,et al.Histopathological findings of the no-reflow phenomenon following coronary intervention for acute coronary syndrome[J].Int Heart J,2005,46(2):327-332. 被引量：1
7[3]Rubenstein MH,Finn AV,Leinbach RC,et al.Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury[J].J Am Coll Cardiol,2004,43(2):287-294. 被引量：1
8[4]Bolognese L,Falsini G,Liistro F,et al.Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions;the EVEREST trial[J].J Am Coll Cardiol,2006,47(3):522-528. 被引量：1
9[5]Kastrati A,Mehilli J,Neumann FJ,et al.Abciximab in patients with acute coronary syndromes undergoing percutaneORS coronary intervention after clopidogrel pretreatment:the ISAR-REACT 2 randomized trial[J].JAMA,2006,295(13):1531-1538. 被引量：1
10[6]Wohrle J,Grebe OC,Nusser T,et al.Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty[J].Circulation,2003,107(14):1840-1843. 被引量：1
